Clinical Trial Search

Primary: Assessment of Maximum Plasma Concentration for AZD9291 After Dosing Alone and in Combination With Rifampicin (Css,Max) — 577.4; 147.5 nanomolar (nM)

Primary: Treatment Recovery — 33; 19 participants — p=0.024

Primary: Time From Study Drug Initiation to Tracheal Extubation — 2.9; 3.4 days — p=0.8

Primary: Change From Baseline in the Crohn's Disease Endoscopic Index of Severity (CDEIS) Blinded Score at Week 6 — -4.8 Score on a scale

Primary: Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine Measured as Progression Free Survival…

Primary: Overall Survival After 24 Hours — 96 participants

Primary: Progression-free Survival — 7.000 months

Primary: Summary of Total Adverse Events (AE) — 39; 58; 35; 11 Events

Primary: Number of Subjects With Any and Grade 3 Solicited General Symptoms and With Solicited General Symptoms Related to Vaccination - Primary Phase of the Study — 82; 76; 72…

Primary: Percentage of Participants With Negative Lowenstein Jensen Cultures at Week 8 — 85; 94; 96 percentage of participants w/LJ cx con

Primary: Area Under the Receiver Operating Characteristic Curve (ROC-AUC) of the Plasma Presepsin Concentration for Discriminating Between SIRS and Sepsis — 0.7218; 0.6901…

Primary: Tear Film Kinetics — 5.590; 6.941 Seconds

Primary: 12-week Abdominal Pain/Abdominal Discomfort Weekly Responder — 250; 206 Participants — p=0.0010

Primary: Change From Baseline in Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Score at Day 85 — 5.78; 5.73; 5.91; 5.67 units on a scale — p=<0.001

Primary: Weekly Response for Abdominal Pain Intensity AND Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks). — 35.7; 34.7…